The $130 Billion Acquisition of Dominion Energy By NextEra – The Special Situations Report Episode #68

Episode Summary

Executive Summary: Episode 68 focuses on two event-driven stories: NextEra Energy’s $110B all-stock bid for Dominion Energy, a highly regulated utility merger driven by surging data-center power demand, and renewed insider buying at GeneDx after a sharp post-earnings selloff. The hosts frame both as long-dated, data-intensive situations where regulatory, operational, and valuation risks matter.

Main Topics: NextEra’s $110B acquisition of Dominion Energy (Priority: 5/5): The hosts discuss the year’s largest announced public-market deal, an all-stock transaction combining two major regulated utilities into a $420B enterprise value company. Regulatory complexity in utility mergers (Priority: 5/5): They emphasize that utility deals face layered approvals from federal and state bodies, often leading to long timelines and elevated deal risk. Data-center power demand as the strategic rationale (Priority: 5/5): The deal is presented as a bet on electricity demand from AI and data centers, especially in Virginia, where Dominion has major exposure. Merger-arbitrage trading angle (Priority: 4/5): The current 7% spread, dividend continuation, and late-2027 close guidance create a potentially tradable but long-duration arbitrage setup, including options strategies. GeneDx insider accumulation (Priority: 5/5): The episode revisits strong insider buying by Keith Meister and Eli Kasten, who bought heavily despite weak fundamentals and a steep stock decline. GeneDx fundamentals and reimbursement challenges (Priority: 5/5): The hosts explain how faster-growing genome testing is reimbursed at lower rates than exome testing, pressuring revenue and causing a major guidance reset. Insiders may be early, but signal conviction (Priority: 4/5): The discussion contrasts poor near-term operating performance with the possibility that board insiders are buying ahead of a multi-year turnaround in genomics and data monetization.

Key Arguments: NextEra/Dominion is attractive strategically because Dominion’s utility footprint and contracted data-center capacity align with rising AI-related electricity demand. Utility mergers are slow and uncertain because they must clear multiple state, federal, and industry-specific regulators, making them difficult for merger arbitrage. The promised $2.25B in bill credits is meant to satisfy regulators concerned about residential customers bearing higher costs from data-center demand. The 7% spread may offer opportunity, but the late-2027 timeline makes this more suitable for options-based or patient arbitrage approaches. GeneDx insiders are buying after a severe drawdown, but the company’s fundamentals have deteriorated due to reimbursement mix shifts and execution issues. Genome testing growth is strong, but because genome reimburses at roughly half the rate of exome in outpatient settings, revenue growth lags volume growth. The hosts view insider buying as potentially early rather than wrong, especially given the size of the stock decline and the board-level conviction behind the purchases.

Data Points: Deal value: $110 billion - Announced acquisition of Dominion Energy by NextEra Energy Combined enterprise value: $420 billion - Estimated value of the combined NextEra-Dominion company Deal structure: All-stock - Dominion acquisition by NextEra Electricity demand of combined company: Roughly 130 gigawatts - Scale of demand discussed in relation to utilities and data centers Homes powered by 1 gigawatt: Around 750,000 homes - Used to explain scale of electricity demand Dominion contracted data-center capacity: Nearly 51 gigawatts - Dominion’s exposure to data-center customers Customer relief package: $2.25 billion - Bill credits/reductions promised over two years to appease regulators Merger spread: 7% - Difference between acquisition price and current trading price Expected close timing: Late 2027 - Guidance for when the NextEra-Dominion deal may close TXNM Energy deal timeline: Nearly 18 months - Reference point for how long utility deals can take to close PNM/Avalanche failed deal duration: 3 years and 2 months - Example of a utility deal that ultimately collapsed Genworth-China Oceanwide failed deal duration: Nearly 4.5 years - Long-running failed transaction used as a comparison GeneDx stock decline: 33% year-to-date - Stock drop before Keith Meister’s initial March purchase Keith Meister March purchase: Around $13.5 million - Initial insider buy discussed from March Vestis insider purchase: Almost $5 million - Past purchase cited as part of Meister’s track record GeneDx follow-on purchase: $60 million - Additional stock purchase by Keith Meister referenced as recent Eli Kasten purchase: Nearly $21 million - Director purchase via Kasten Capital Q1 2026 EPS: -28 cents per share - GeneDx earnings result versus expectations Q1 2026 EPS consensus: -1 cent per share - Street estimate for GeneDx EPS Q1 2026 revenue: $102 million - GeneDx quarterly revenue Q1 2026 revenue consensus: $112 million - Street estimate for GeneDx revenue Genome share of outpatient volume: Approximately 40% - Mix shift toward lower-reimbursing genome testing Outpatient exome price after denials: Around $4,000 per test - Blended reimbursement reference point Outpatient genome price after denials: About half of exome - Lower reimbursement rate for genome testing ARR decline: 12% quarter-over-quarter - Average reimbursement rate for GeneDx Testing volume growth: 34% year over year - GeneDx quarterly volume growth Revenue growth: 27% year over year - GeneDx quarterly revenue growth Goodwill impairment: Roughly $31 million - Non-cash charge for Fabric Genomics Guidance cut: $65 million midpoint reduction - Management’s full-year 2026 revenue guidance cut Operating loss: $57.5 million - One of the factors cited in litigation concerns Single-day stock drop: 49% - Post-earnings decline that triggered scrutiny Medicaid coverage states: 38 states - Current coverage for exome or genome testing

Pivotal Quotes: "anything you want to know about why something’s happening or why I think something is working, you can just say AI or data centers, and there you have it." — Tamanda Surya: Explaining the core investment thesis behind the NextEra-Dominion merger "When it comes to insurance company deals and utility deals, I try to stay as far away as I can unless they’re especially attractive for some reason." — Asif Surya: Discussing the difficulty and risk profile of heavily regulated transactions "Insiders always tend to be early" — Asif Surya: Summarizing why strong insider buying at GeneDx may precede a turnaround but not immediate performance

Implications: Listeners should see utility mergers as long, regulator-heavy situations where demand trends can justify deals but timing risk is substantial. GeneDx shows how insider buying can signal conviction in a beaten-down story even while fundamentals and reimbursement dynamics remain weak.